Liver transplantation for porphyria: Who, when, and how?

Liver Transplantation

Volumn 13, Issue 9, 2007, Pages 1219-1227

  Seth, Avnish Kumar ^a   Badminton, Michael N ^b   Mirza, Darius ^a   Russell, Scott ^a   Elias, Elwyn ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANALGESIC AGENT; ANTACID AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DIURETIC AGENT; ENOXAPARIN; HEMATIN; HEMIN; IMMUNOSUPPRESSIVE AGENT; LINEZOLID; MAGNESIUM SULFATE; PENTAMIDINE; PORPHOBILINOGEN SYNTHASE; PROTOPORPHYRIN; TACROLIMUS; TEICOPLANIN; UNINDEXED DRUG;

ANEMIA; ANESTHESIA; ASSISTED VENTILATION; AUTOSOMAL RECESSIVE DISORDER; BLOOD TRANSFUSION; BONE DENSITY; CALCIUM DEFICIENCY; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; DETERIORATION; DRUG CONTRAINDICATION; DRUG SAFETY; ERYTHROPOIETIC PROTOPORPHYRIA; GRAFT SURVIVAL; HEMATOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; NERVE INJURY; OSTEOPOROSIS; PARENTERAL NUTRITION; PATHOGENESIS; PHLEBITIS; PHLEBOGRAPHY; PNEUMOCYSTIS PNEUMONIA; PORPHYRIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; TISSUE INJURY; VANCOMYCIN RESISTANT ENTEROCOCCUS; VEIN THROMBOSIS; VITAMIN D DEFICIENCY;

CARCINOMA, HEPATOCELLULAR; GRAFT SURVIVAL; HEMIN; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PORPHYRIAS, HEPATIC; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS;

EID: 34648839993     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21261     Document Type: Review

References (60)

1. Soonawalla ZF, Orug T, Badminton MN, Elder GH, Rhodes JM, Bramhall SR, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004;363:705-706.
2. Stojeba N, Meyer C, Jeanpierre C, Perrot F, Hirth C, Pottecher, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 2004;10:935-938.
3. Thunel S, Henrichson A, Floderus Y, Groth CG, Eriksson BG, Barkholt L, et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem 1992;30:599-606.
4. Pimstone NR. Roles and pitfalls of transplantation in human porphyrias. Liver Transpl 2005;1:1460-1462.
5. McGuire BM, Bonkovsky HL, Carithers RL Jr, Chung RT, Goldstein LI, Lake JR et al. Liver transplantation for erythropoietic protophyria liver disease. Liver Transpl 2005;11: 1590-1596.
6. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005;84: 48-60.
7. Human Genome Mutation Database. Available at: http://www.hgmd.org. Last accessed: July 16, 2007.
8. Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med 1990;150:1469-1474.
9. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998;18:43-52.
10. Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A. Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 1983;85: 1131-1137.
11. Church SE, McColl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyrias. Nephrol Dial Transplant 1992;7:986-990.
12. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000;248: 319-325.
13. Anderrson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996;240:195-201.
14. Andant C, Puy H, faivre J, Deybach JC. Acute hepatic porphyrias and primary liver cancer [Letter]. N Engl J Med 1998;338:1853-1854.
15. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Claus A, Pierach MD, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439-450.
16. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Intern Med 1975;83:851-864.
17. Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Semin Liver Dis 1998;18:53-55.
18. Grant P, Insall R. Porta-cath complicated by IVC thrombosis. Eur J Intern Med 2005;16:200-201.
19. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999;9:3-14.
20. Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem 2006;52:650-656.
21. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, Kowdley KV. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl Surg 1999;5:369-374.
22. Hunter GA, Rivera E, Ferreira GC. Supraphysiological concentrations of 5-aminolevulinic acid dimerize in solution to produce superoxide radical anions via a protonated dihydropyrazine intermediate. Arch Biochem Biophys 2005;437:128-137.
23. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941-966.
24. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Kinkenstedt G, Muehllechner P, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005;11:960-966.
25. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Group. N Engl J Med 1995;333:1437-1443.
26. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299.
27. Barone GW, Gurley BJ, Anderson KE, Ketel BL, Abul-Ezz SR. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol 2001;41:113-115.
28. Ozdemir D, Karabay O, Sencan I. The use of teicoplanin in a patient with acute intermittent porphyria. J Chemother 2005;17:573-574.
29. James MFM, Hift RJ, Porphyrias. Br J Anaesth 2000;85: 143-153.
30. Cooper R. Anaesthesia for porphyria using propofol. Anaesthesia 1988;43:611-613.
31. Hughes PJ. Propofol in acute porphyrias. Anaesthesia 1990;45:415-417.
32. McLoughlin C. Use of propofol in a patient with acute porphyria. Br J Anaesth 1989:62;371-373.
33. Rigg J, Petts V. Acute porphyria and propofol. Anaesthesia 1993;48:1108-1109.
34. Kantor G, Rolbin SH. Acute intermittent porphyria and Caesarean delivery. Can J Anaesth 1992;39:282-285.
35. Lin YC, Chen L. Atracurium in a patient with acute intermittent porphyria. Anesth Analg 1990;71:440-441.
36. McNeill MJ, Bennett A. Use of regional anaesthesia in a patient with acute porphyria. Br J Anaesth 1990;64:371-373.
37. Cox TM, Alexander GJ, Sarkany RP. Protoporphyria. Semin Liver Dis 1998;18:85-93.
38. Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Da Silva V, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002;30:27-28.
39. Thunell S, Harper P, Brun A. Porphyrins, porphyrin metabolism and porphyrias. IV. Pathophysiology of erythyropoietic protoporphyria - diagnosis, care and monitoring of the patient. Scand J Clin Lab Invest 2000:60:581-604.
40. Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN. Erythropoietic protoporphyria in the United Kingdom: clinical features and effect on quality of life. Br J Dermatol 2006;155:574-581.
41. Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria, a 20-year study. Clin Biochem 1989;22:223-229.
42. Cripps DJ, Scheur PJ. Hepatobiliary changes in erythropoietic porphyria. Arch Pathol 1965;80:500-502.
43. Klatskin G, Bloomer JR. Birefringence of hepatic pigment deposits in erythropoietic porphyria; specificity and sensitivity of polarization microscopy in the identification of hepatic porphyrin deposits. Gastoenterology 1974; 67:294-297.
44. Avner DL, Lee RG, Berenson MM. Protoporphyrin induced cholestasis in the isolated in-situ perfused rat liver. J Clin Invest 1981;67:385-394.
45. Avner DL, Larsen R, Berenson MM. Inhibition of liver surface membrane Na, K-adenosine triphosphatase, Mg-adenosine triphosphatase and 5′-nucleotidase activities by protoporphyrin. Observations in vitro and in the perfused rat liver. Gastroenterology 1983;85:700-706.
46. Meerman L, Koopen NR, Bloks V, VanGoor H, Havinga R, Wolthers BG, et al. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 1999;117:696-705.
47. Meerman L. Erythropoietic porphyria. An overview with emphasis on the liver. Scand J Gastroenterol 2000;35:79-85.
48. Reichheld JH, Katz E, Banner BF, Szymanski IO, Saltzman JR, Bonkovsky HL. The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. Transplantation 1999;67:922-928.
49. Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002:73: 469-472.
50. Polson RJ, Lim CK, Rolles K, Calne RY, Williams R. The effect of liver transplantation in a 13-year old boy with erythropoietic porphyria. Transplantation 1988;46:386-389.
51. Bloomer JR, Weimer MK, Bossenmaier IC, Snover DC, Payne WD, Ascher NL. Liver transplantation in a patient with protoporphyria. Gastroenterology 1989;97:188-194.
52. Johnson JA, Fusaro RM. Liver transplantation in patients with erythropoietic protoporphyria. Gastroenterology 1990;96:1726-1727.
53. Mion FBC, Faure JL, Berger R, McGragor B, Perrot H, Paliard P. Liver transplantation for erythropoietic porphyria. J Hepatol 1992;16:203-207.
54. Bloomer JR, Rank JM, Payne WD, Snover DC, Sharp HL, Zwiener RJ, et al. Follow up after liver transplantation for protoporphyric liver disease. Liver Transpl Surg 1996;2: 269-275.
55. Herbert A, Corbin D, Williams A, Thompson D, Buckels J, Elias E. Erythropoictic protoporphyria: unusual skin and neurological problems after liver transplantation. Gastroenterology 1991;100:1753-1757.
56. Meerman L, Verwer R, Sloof MJH, Van Hattum J, Beukeveld GJJ, Kleibeuker JH, et al. Perioperative measures during liver transplantation for erythropoietic protoporphyria. Transplantation 1994;57:155-158.
57. Rank JM, Carithers R, Bloomer J. Evidence of neurological dysfunction in end-stage protoporphyric liver disease. Hepatology 1993;18:1404-1409.
58. Dellon ES, Szczepiorkowski ZM, Dxik WH, Graeme-Cook F, Ades A, Bloomer JR, et al. Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoletic protoporphyria. Transplantation 2002;73:911-915.
59. Poh-fitzpatrick MB, Wang X, Anderson KE, Bloomer JR, Bolwell B, Lichtin AE. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukaemia in a patient heteroallelic for ferrochelatatse gene mutations. J Am Acad Dermatol 2002; 46:861-866.
60. Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006;118:e1896-e1899.